Search CTL/CD8+ T-Cell Epitope Database

Found 4 matching records:

Displaying record number 56204

Download this epitope record as JSON.

HXB2 Location	gp160(205-213) gp120(205-213) DNA(6837..6863)	gp160 Epitope Map
Author Location	Env(250-)
Epitope	`CPKVSFEPI`	Epitope Alignment
Species (MHC/HLA)	human(B*07:02)
Immunogen	vaccine
Country	Botswana, United States
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay
Keywords	vaccine antigen design

Vaccine Details

Vaccine type	DNA, polyepitope
Vaccine strain	multiple epitope immunogen

Notes

This is a trial of a multi-epitope DNA vaccine that included 21 CTL epitopes, which are conserved among clades A,B,C,D and CRFs and are supertype binding peptides of A1, A3 and B7 supertypes. Participants were from US and Botswana.
The vaccine was safe and well-tolerated, but the rate of CTL induction was low. CD8+ responses (and no CD4+ responses) were detected in 3/26 subjects using chromium release assay and in 2/42 subjects using IFN-γ ELISPOT assay.
This epitope was included in the vaccine.

References

Gorse2008a Geoffrey J. Gorse, Lindsey R. Baden, Margaret Wecker, Mark J. Newman, Guido Ferrari, Kent J. Weinhold, Brian D. Livingston, Tonya L. Villafana, Hongli Li, Elizabeth Noonan, Nina D. Russell, and HIV Vaccine Trials Network. Safety and Immunogenicity of Cytotoxic T-Lymphocyte Poly-Epitope, DNA Plasmid (EP HIV-1090) Vaccine in Healthy, Human Immunodeficiency Virus Type 1 (HIV-1)-Uninfected Adults. Vaccine, 26(2):215-223, 10 Jan 2008. PubMed ID: 18055072. Show all entries for this paper.

Displaying record number 62865

Download this epitope record as JSON.

HXB2 Location	gp160(205-213) gp120(205-213) DNA(6837..6863)	gp160 Epitope Map
Author Location	Env( JR-CSF)
Epitope	`CPKVSFEPI`	Epitope Alignment
		Show epitope variants
Epitope Name	CI9
Subtype	B
Species (MHC/HLA)	humanized mouse(B*07:02)
Immunogen	HIV-1 infection, vaccine, virus
Experimental methods	Cytokine production, IVAG challenge, Other, T-cell Elispot
Keywords	vaccine-induced immune responses, escape, assay or method development

Vaccine Details

Vaccine type	virus, PLG microparticle, recombinant protein
Vaccine strain	B clade
Vaccine component	Gag, virus

Notes

This comprehensive longitudinal study is the first to document that clinically-relevant HIV-1-specific T cell responses can be induced by rapid prime (recombinant Gag polyprotein adsorbed to PLGA microspheres) with boost (Gag-expressing HSV-1) immunization in 31 BLT humanized mice, each generated from 1/4 individual donors with distinct human HLA alleles, during the first 12 weeks of HIV-1_JR-CSF infection. Gag-immunized BLT humanized mice were capable of mounting strong and broadly directed HIV-1 specific IFNγ+ T cell responses that drive CTL epitope viral evolution and enhance Gag-specific post-challenge responses while also associating with significant, yet modest, reductions in early HIV-1 viremia.
No pre-challenge Gag-specific responses were detected and impact on early HIV-1 viremia was only transient. Authors suggest that improvements in immunization strategy and/or additional maturation of recapitulated human immune system may be beneficial for further vaccine studies.
Origination and increasing frequency of epitope variants were generally observed in individual BLT humanized mice infected with HIV-1_JR-CSF. At 12 weeks post infection, complete or nearly complete escape (<10% of inoculum sequence) was observed in 1 CTL epitope in 11/25 mice, 2 CTL epitopes in 6/25 mice and 3 CTL epitopes in 5/25 mice.
At 12 weeks post HIV-1_JR-CSF-infection, 9/17 BLT humanized mice with donor tissue expressing HLA-I alleles B0702/B5801 displayed evolution of B*07:02-restricted epitope Env CI9. Within a single mouse, the frequency of an individual variant was up to 83% while the frequency of HIV-1_JR-CSF CI9 sequence CPKVSFEPI was 16-94% in these 9 mice.

References

Claiborne2019 Daniel T. Claiborne, Timothy E. Dudek, Colby R. Maldini, Karen A. Power, Musie Ghebremichael, Edward Seung, Elizabeth F. Mellors, Vladimir D. Vrbanac, Katharine Krupp, Abigail Bisesi, Andrew M. Tager, David M. Knipe, Christian L. Boutwell, and Todd M. Allen. Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia. J. Virol., 93(20), 15 Oct 2019. PubMed ID: 31375576. Show all entries for this paper.

Displaying record number 56547

Download this epitope record as JSON.

HXB2 Location	gp160(205-213) gp120(205-213) DNA(6837..6863)	gp160 Epitope Map
Author Location	Env
Epitope	`CPKVSFEPI`	Epitope Alignment
Epitope Name	Env250
Subtype	B
Species (MHC/HLA)	human(B7)
Immunogen	vaccine
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	vaccine antigen design

Vaccine Details

Vaccine type	polyepitope
Vaccine component	other

Notes

DNA vaccine EP HIV-1090 evaluation in patients receiving ART was done. This vaccine is composed of multiple CTL epitopes, all associated with certain HLA supertypes. Differences of CTL response rate in vaccine and placebo recipients however, was not significant.
CPKVSFEPI is an Env epitope encoded in the EP HIV-1090 polyepitope vaccine.

References

Wilson2008 Cara C. Wilson, Mark J. Newman, Brian D. Livingston, Samantha MaWhinney, Jeri E. Forster, Jim Scott, Robert T. Schooley, and Constance A. Benson. Clinical Phase 1 Testing of the Safety and Immunogenicity of an Epitope-Based DNA Vaccine in Human Immunodeficiency Virus Type 1-Infected Subjects Receiving Highly Active Antiretroviral Therapy. Clin. Vaccine Immunol., 15(6):986-994, Jun 2008. PubMed ID: 18400976. Show all entries for this paper.

Displaying record number 56526

Download this epitope record as JSON.

HXB2 Location	gp160(205-213) gp120(205-213) DNA(6837..6863)	gp160 Epitope Map
Author Location	Env
Epitope	`CPKVSFEPI`	Epitope Alignment
Epitope Name	Env250
Subtype	A, B, D
Species (MHC/HLA)	human, mouse(B7 supertype)
Immunogen	HIV-1 infection
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	binding affinity, supertype, vaccine-induced immune responses, HLA cross-presentation

Notes

21 supertype-A2, -A3 and -B7-restricted epitopes predicted to be immunogenic by HLA-peptide binding motifs and phenotypic frequency in individuals were recognized by HIV-1+ subjects in ELISpot assays and shown to bind with high affinity to minimum 3 HLA-alleles of the restricting supertype. These epitopes were included in DNA vaccine EP HIV-1090 that avoided immunodominant responses and did not restrict subject immunity to predicted HLA-type when tested in mice. Transgenic mice mounted a vaccine-response similar to that induced by ELISpot assay in humans.
Epitope CPKVSFEPI of the HLA-B7 supertype bound most strongly to HLA-B*5401, -B*0702 and -B*5101 and also to -B*5301 and -B*3501. It was conserved 75% in subtype A, 79% in B, 50% in subtype D. 3/16 HLA-B7 supertype expressing HIV-1+ subjects mounted a positive ELISpot response to Env250.

References

Wilson2003 Cara C. Wilson, Denise McKinney, Michelle Anders, Samantha MaWhinney, Jeri Forster, Claire Crimi, Scott Southwood, Alessandro Sette, Robert Chesnut, Mark J Newman, and Brian D Livingston. Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1. J. Immunol., 171(10):5611-5623, 15 Nov 2003. PubMed ID: 14607970. Show all entries for this paper.